BR112022014212A2 - Métodos de análise de uma amostra incluindo uma proteína de interesse e para determinar a estabilidade de uma proteína de interesse - Google Patents

Métodos de análise de uma amostra incluindo uma proteína de interesse e para determinar a estabilidade de uma proteína de interesse

Info

Publication number
BR112022014212A2
BR112022014212A2 BR112022014212A BR112022014212A BR112022014212A2 BR 112022014212 A2 BR112022014212 A2 BR 112022014212A2 BR 112022014212 A BR112022014212 A BR 112022014212A BR 112022014212 A BR112022014212 A BR 112022014212A BR 112022014212 A2 BR112022014212 A2 BR 112022014212A2
Authority
BR
Brazil
Prior art keywords
interest
protein
methods
stability
analysis
Prior art date
Application number
BR112022014212A
Other languages
English (en)
Other versions
BR112022014212B1 (pt
Inventor
Zhao Yiming
Chen Hunter
Wang Shao-Chun
Riehlman Timothy
Carreau Gabriel
Wang Ying
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Priority to BR122023021668-7A priority Critical patent/BR122023021668A2/pt
Publication of BR112022014212A2 publication Critical patent/BR112022014212A2/pt
Publication of BR112022014212B1 publication Critical patent/BR112022014212B1/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/24—Extraction; Separation; Purification by electrochemical means
    • C07K1/26—Electrophoresis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/02—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance
    • G01N27/04—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance
    • G01N27/041—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance of a solid body
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G01N27/44756—Apparatus specially adapted therefor
    • G01N27/44791—Microapparatus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/38—Post-translational modifications [PTMs] in chemical analysis of biological material addition of carbohydrates, e.g. glycosylation, glycation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Electrochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

MÉTODOS DE ANÁLISE DE UMA AMOSTRA INCLUINDO UMA PROTEÍNA DE INTERESSE E PARA DETERMINAR A ESTABILIDADE DE UMA PROTEÍNA DE INTERESSE. A divulgação refere-se a métodos de análise de uma proteína de interesse modificada pós-tradução usando eletroforese, os métodos compreendendo a deglicosilação da proteína de interesse após a marcação.
BR112022014212-9A 2020-01-21 2021-01-20 Métodos de análise de uma amostra incluindo uma proteína de interesse BR112022014212B1 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122023021668-7A BR122023021668A2 (pt) 2020-01-21 2021-01-20 Método para determinar a estabilidade de uma proteína de interesse

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062963646P 2020-01-21 2020-01-21
US62/963,646 2020-01-21
PCT/US2021/014111 WO2021150558A1 (en) 2020-01-21 2021-01-20 Deglycosylation methods for electrophoresis of glycosylated proteins

Publications (2)

Publication Number Publication Date
BR112022014212A2 true BR112022014212A2 (pt) 2022-09-20
BR112022014212B1 BR112022014212B1 (pt) 2024-01-23

Family

ID=74798013

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122023021668-7A BR122023021668A2 (pt) 2020-01-21 2021-01-20 Método para determinar a estabilidade de uma proteína de interesse
BR112022014212-9A BR112022014212B1 (pt) 2020-01-21 2021-01-20 Métodos de análise de uma amostra incluindo uma proteína de interesse

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122023021668-7A BR122023021668A2 (pt) 2020-01-21 2021-01-20 Método para determinar a estabilidade de uma proteína de interesse

Country Status (11)

Country Link
US (2) US11835527B2 (pt)
EP (2) EP4085253B1 (pt)
JP (2) JP7342279B2 (pt)
KR (2) KR20230088853A (pt)
CN (1) CN115398236A (pt)
AU (2) AU2021209866B2 (pt)
BR (2) BR122023021668A2 (pt)
CA (1) CA3165060C (pt)
IL (2) IL294765B2 (pt)
MX (1) MX2022008973A (pt)
WO (1) WO2021150558A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7342279B2 (ja) 2020-01-21 2023-09-11 リジェネロン・ファーマシューティカルズ・インコーポレイテッド グリコシル化タンパク質の電気泳動のための脱グリコシル化方法

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859581A (en) 1986-03-10 1989-08-22 Board Of Regents, The University Of Texas System Endoglycosidase assay
DE59010908D1 (de) 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6972326B2 (en) 2001-12-03 2005-12-06 Molecular Probes, Inc. Labeling of immobilized proteins using dipyrrometheneboron difluoride dyes
US6927004B2 (en) 2002-03-08 2005-08-09 Asml Netherlands B.V. Mask for use in lithography, method of making a mask, lithographic apparatus, and device manufacturing method
DE10258150A1 (de) 2002-12-10 2004-07-08 Dyomics Gmbh Hydrophile Marker auf der Basis von Benzopyrylo-Polymethinen
JP4568551B2 (ja) * 2004-07-28 2010-10-27 一晃 掛樋 糖たん白質糖鎖の分析方法及び非標識糖鎖の製造方法
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
PL2178916T3 (pl) 2007-07-31 2015-08-31 Regeneron Pharma Ludzkie przeciwciała przeciwko ludzkiemu CD20 i sposób ich zastosowania
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
WO2010122460A1 (en) 2009-04-20 2010-10-28 Pfizer Inc. Control of protein glycosylation and compositions and methods relating thereto
EP2975051B1 (en) 2009-06-26 2021-04-14 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
JOP20190250A1 (ar) 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
AR083044A1 (es) 2010-09-27 2013-01-30 Regeneron Pharma Anticuerpos anti-cd48 y usos de los mismos
CN106267189B (zh) 2010-10-06 2021-02-26 瑞泽恩制药公司 含有抗白介素-4受体(il-4r)的抗体的稳定制剂
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
EP2686680B1 (en) 2011-03-18 2018-06-13 Biotium Inc. Fluorescent dyes, fluorescent dye kits, and methods of preparing labeled molecules
AR087329A1 (es) 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
LT2780368T (lt) 2011-11-14 2018-03-12 Regeneron Pharmaceuticals, Inc. Kompozicijos ir būdai raumenų masės padidinimui ir raumenų sustiprinimui, specifiškai antagonizuojant gdf8 ir (arba) aktiviną a
EP2807190B1 (en) 2012-01-23 2018-12-26 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ang2 antibodies
JO3820B1 (ar) 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
WO2013192530A2 (en) * 2012-06-21 2013-12-27 Children's Medical Center Corporation Methods and reagents for glycoproteomics
TW201843172A (zh) 2012-06-25 2018-12-16 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
EA028244B1 (ru) 2012-08-13 2017-10-31 Ридженерон Фармасьютикалз, Инк. АНТИТЕЛА К PCSK9 C pH-ЗАВИСИМЫМИ ХАРАКТЕРИСТИКАМИ СВЯЗЫВАНИЯ
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
US9637535B2 (en) 2013-03-15 2017-05-02 Regeneron Pharmaceuticals, Inc. IL-33 antagonists and uses thereof
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
CA2919724C (en) * 2013-08-20 2018-06-19 Advanced Polymer Monitoring Technologies, Inc. Characterization of polymer and colloid solutions
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JP6632984B2 (ja) 2014-03-11 2020-01-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗ＥＧＦＲｖＩＩＩ抗体およびその使用
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
EP3636073B1 (en) 2014-05-05 2023-11-15 Regeneron Pharmaceuticals, Inc. Humanized c5 and c3 animals
JO3701B1 (ar) 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
EP3149034B1 (en) * 2014-05-30 2022-07-13 New England Biolabs, Inc. Deglycosylation reagents and methods
CN105277398A (zh) * 2014-06-12 2016-01-27 中国科学院大连化学物理研究所 一种特殊糖肽富集和鉴定的方法
US20160068884A1 (en) 2014-09-09 2016-03-10 Bio-Techne Corporation Methods for determining presence or absence of glycan epitopes on glycoproteins
EA201790377A1 (ru) 2014-09-16 2017-08-31 Регенерон Фармасьютикалз, Инк. Антитела к глюкагону и их применения
EP4033223A1 (en) * 2014-10-30 2022-07-27 Waters Technologies Corporation Methods for the rapid preparation of labeled glycosylamines and for the analysis of glycosylated biomolecules producing the same
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
US10509042B2 (en) 2015-04-30 2019-12-17 Dh Technologies Development Pte. Ltd. Identification of glycosylation forms
US20160348139A1 (en) * 2015-05-29 2016-12-01 Michael J. KIMZEY Use of bile detergents to denature glycoproteins prior to enzymatic digestion
US11035862B2 (en) * 2016-08-17 2021-06-15 Agilent Technologies, Inc. Use of mild electrophiles to reduce artifacts in analyzing glycans released from glycoproteins or glycopeptides
WO2018067449A1 (en) * 2016-10-05 2018-04-12 Bio-Techne Corporation Methods and kits for assaying endoglycosidase activity
JP2020504997A (ja) * 2016-11-18 2020-02-20 バイオコン・リミテッド 迅速で効率的な糖タンパク質の脱グリコシル化
CA3089655A1 (en) * 2018-03-19 2019-09-26 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
JP7342279B2 (ja) 2020-01-21 2023-09-11 リジェネロン・ファーマシューティカルズ・インコーポレイテッド グリコシル化タンパク質の電気泳動のための脱グリコシル化方法

Also Published As

Publication number Publication date
EP4085253A1 (en) 2022-11-09
CN115398236A (zh) 2022-11-25
KR20230088853A (ko) 2023-06-20
IL294765B1 (en) 2023-08-01
BR122023021668A2 (pt) 2024-01-09
US20210223256A1 (en) 2021-07-22
CA3165060C (en) 2023-06-20
US20240053353A1 (en) 2024-02-15
EP4085253B1 (en) 2024-03-13
JP2023506090A (ja) 2023-02-14
WO2021150558A1 (en) 2021-07-29
BR112022014212B1 (pt) 2024-01-23
AU2021209866B2 (en) 2023-07-06
JP2023166478A (ja) 2023-11-21
JP7342279B2 (ja) 2023-09-11
IL294765B2 (en) 2023-12-01
IL303596A (en) 2023-08-01
EP4354145A2 (en) 2024-04-17
CA3165060A1 (en) 2021-07-29
KR102544013B1 (ko) 2023-06-19
AU2021209866A1 (en) 2022-08-18
MX2022008973A (es) 2022-08-11
AU2023226678A1 (en) 2023-09-28
US11835527B2 (en) 2023-12-05
IL294765A (en) 2022-09-01
KR20220121892A (ko) 2022-09-01

Similar Documents

Publication Publication Date Title
BR112017017025A2 (pt) métodos e composições para analizar componentes celulares
CO2021003724A2 (es) Proteínas de fijación a sirpα y métodos de uso de estas
BR112018071686A2 (pt) exibição de proteínas integrais de membrana em vírions extracelulares envelopados de poxvírus
BR112019006930A2 (pt) dispositivos e métodos para análise de amostra
CU23791A3 (es) Método para la producción de proteínas y anticuerpos mejorados
ES2531168T3 (es) Perfiles compuestos de antígenos celulares y proteínas diana de transducción de señales para el análisis y la gestión de la asistencia clínica de los cánceres hematológicos
BR112020000209A8 (pt) moléculas de ligação que modulam uma atividade biológica expressa por uma célula
CA2798517A1 (en) Systems and methods of detecting and demonstrating hair damage via evaluation of protein fragments
AR117402A1 (es) Ensayos de electroforesis capilar de microchip y reactivos
BR112013025629A2 (pt) padrão quantitativo para espectrometria de massa de proteínas
BR112022003241A2 (pt) Fontes de proteína não animal com propriedades fucionais
BR112022014212A2 (pt) Métodos de análise de uma amostra incluindo uma proteína de interesse e para determinar a estabilidade de uma proteína de interesse
BRPI0918233B8 (pt) métodos de triagem para a lesão pulmonar aguda e doença do enxerto contra hospedeiro relacionada à transfusão ou transplante, kits e uso de polipeptídeos
BR112022014992A2 (pt) Métodos de caracterização de uma amostra, de tratamento, para fazer uma composição e de caracterização de uma amostra, e, composição
Mazorra-Manzano et al. A capillary electrophoresis method for the determination of hydroxyproline as a collagen content index in meat products
EA202191931A1 (ru) Способ характеризации видимых и/или невидимых частиц в биологических препаратах
DE50105263D1 (de) Verfahren zur analyse von proteinen
BR112022008075A2 (pt) Métodos de seqüênciamento de proteínas de célula única e de ácido nucleico
BRPI0406265B8 (pt) método para análise por eletroforese capilar, método para pesquisa e tipagem de proteínas monoclonais, método de preparação de anticorpos modificados sobrecarregados negativamente e kit para detecção e tipagem de proteínas monoclonais
BR112022006866A2 (pt) Métodos para caracterizar proteínas de células hospedeiras
BR112019007138A2 (pt) método e sistema de análise para testagem de uma amostra
BR112021012247A2 (pt) Método de extração de proteína de material de planta de canábis
CL2015003047A1 (es) Método ex vivo para detectar precozmente injuria renal aguda en pacientes críticos, que comprende la mediciom en una muestra de tres proteinas como biomarcadores, factor de crecimiento fibroblástico 23, klotho y eritropoyetina
MX2020001818A (es) Isoelectroenfoque capilar con imagenes para analizar variantes de proteina en una matriz de muestra.
Muller et al. Disease state, age, sex, and post-mortem time-dependent expression of proteins in AD vs. control frontal cortex brain samples

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122023021668-7 PROTOCOLO 870230092379 EM 18/10/2023 16:13.

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/01/2021, OBSERVADAS AS CONDICOES LEGAIS